Dr. Ross David Merkin, MD

Dr. Merkin practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Merkin's NPI, 1295181998, was assigned on May 11, 2016. Dr. Merkin holds Massachusetts license 1015276.

Dr. Merkin's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Merkin's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Merkin is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Merkin to 3 more hospitals, 3 medical groups and 1 community health center, each named with a free account. Dr. Merkin's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Merkin practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Merkin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Merkin is licensed in Massachusetts.

CMS data shows 454 Medicare services from Dr. Merkin across 8 procedure codes in 2024, for 134 Medicare patients. Medicare paid $34,082 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 134 Medicare patients who saw Dr. Merkin in 2024. The largest group is 75 to 84, with 54 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Merkin's median patient age at 76, with 25% women.

In 2024, Dr. Merkin wrote 76 Medicare Part D claims for 32 patients. 89% of them were for generic drugs. They cover 13 drugs, with $39,887 in total drug cost. In 2019, CMS named 767 claims across 33 drugs.

Dr. Merkin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Merkin as offering telehealth.

Dmand AI links 16 papers to Dr. Merkin, published from 2013 to 2025. 2025 was the busiest year, with 6. The most frequent topics are Immune Checkpoint Inhibitors, Head and Neck Neoplasms and Squamous Cell Carcinoma of Head and Neck. Dr. Merkin has published most often in J Immunother Cancer. Dr. Merkin's most frequent co-authors are Thomas J. Roberts, MBA, MD, Lori J. Wirth, MD and Daniel Faden, MD.

CMS Open Payments shows 2 general payments to Dr. Merkin from 2 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 65% of the total. Tempus AI, Inc paid the most, $86.